Skip Ribbon Commands
Skip to main content
Translate
Donations
menu iconMenu
search iconSearch

Indications and Duration of Therapy

Recommended Therapeutic Range and Duration of Therapy with Warfarin

Adapted from the 9th Edition of the CHEST guidelines:

Indication INR Range Duration
Antiphospholipid Syndrome 2.0-3.0 indefinite (2B)
DVT and PE
Transient/reversible risk factor 2.0-3.0 3 months (1B)
Unprovoked 2.0-3.0 at least 3 months (1B) then reevaluate
Second episode of unprovoked 2.0-3.0 extended (1B)
Non-Valvular Atrial Fibrillation/Atrial Flutter
CHADS2 = 0 (low CVA risk) N/A no therapy (2B) or ASA 75-325mg (2B)
CHADS2 = 1 (intermediate CVA risk) N/A  dabigatran (2B)
CHADS2 ≥ 2 (high CVA risk) N/A dabigatran (2B)
With mitral stenosis 2.0-3.0 long-term (1B)
With stable CAD 2.0-3.0 long-term (2C)
Prior to/following cardioversion to NSR 2.0-3.0 3 weeks/4weeks (1B)
Mechanical Heart Valve
Aortic 2.0-3.0 long-term (1B)
Mitral 2.5-3.5 long-term (2C)
Bioprosthetic heart valve
Aortic N/A aspirin 50-100mg (2C)
Mitral 2.0-3.0 3 months then switch to ASA (2C)
Cardioembolic Ischemic Stroke N/A dabigatran (2B)

Reference:

Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 2012

Strength of Recommendations Grading System

 

 

From the 8th edition of the CHEST guidelines:

Indication INR Range Duration
Antiphospholipid Syndrome
No additional risk factors 2.0-3.0 indefinite (1A)
Recurrent events with therapeutic INRs 2.5-3.5 indefinite (2C)
DVT and PE
Transient/reversible risk factor 2.0-3.0 3 months (1A)
Unprovoked 2.0-3.0 at least 3 months (1A) then reevaluate (1C)
Second episode of unprovoked 2.0-3.0 long-term (1A)
After 3 months at 2.0-3.0 1.5-1.9 long-term (1A)
With active cancer after LMWH for 3-6 months 2.0-3.0 indefinite (1A) or until CA resolved (1C)
Atrial Fibrillation/Atrial Flutter
With prior CVA/TIA or systemic embolism 2.0-3.0 long-term (1A)
CHADS2 = 0 N/A aspirin 75-325mg (1B)
CHADS2 = 1 2.0-3.0 long-term (1A) or aspirin 75-325mg (1B)
CHADS2 ≥ 2 2.0-3.0 long-term (1A)
With mitral stenosis 2.0-3.0 long-term (1B)
Following open heart surgery 2.0-3.0 4 weeks (1B)
Prior to/following cardioversion to NSR 2.0-3.0 3 weeks/4weeks (1C)
Mechanical Heart Valve
Aortic bileaflet or tilting disk 2.0-3.0 long-term (1B)
Mitral bileaflet or tilting disk 2.5-3.5 long-term (1B)
Aortic or mitral caged ball or caged disk 2.5-3.5 long-term (1B)
Any valve with additional risk factor 2.5-3.5 long-term (1B)
Any valve + suffer embolism with target INR increase + add ASA long-term (2C)
Bioprosthetic heart valve
Aortic N/A aspirin 50-100mg
Mitral 2.0-3.0 3 months then switch to ASA (1B)
With prior h/o systemic embolism 2.0-3.0 3 months then reassess (1C)
With LA thrombus 2.0-3.0 until resolution (1C)
Cardioembolic Ischemic Stroke 2.0-3.0 long-term (1A)